{"id":"fcn-159","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, FCN-159 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.","oneSentence":"FCN-159 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:38.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06553365","phase":"PHASE2","title":"Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-15","conditions":"Nerve Sheath Tumor","enrollment":30},{"nctId":"NCT07024394","phase":"PHASE1, PHASE2","title":"Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2025-06-12","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma, NF1","enrollment":65},{"nctId":"NCT07004075","phase":"PHASE3","title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2025-06-30","conditions":"Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration","enrollment":102},{"nctId":"NCT06913725","phase":"PHASE2","title":"An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-02-24","conditions":"Brain Arteriovenous Malformations","enrollment":10},{"nctId":"NCT05913037","phase":"PHASE3","title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2023-06-20","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma, NF1","enrollment":167},{"nctId":"NCT05997602","phase":"PHASE2","title":"To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH","status":"RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2023-09-28","conditions":"Langerhans Cell Histiocytosis, LCH","enrollment":56},{"nctId":"NCT04954001","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2021-03-26","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma, NF1","enrollment":160},{"nctId":"NCT03932253","phase":"PHASE1","title":"MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)","status":"SUSPENDED","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2019-03-21","conditions":"Melanoma","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FCN-159","genericName":"FCN-159","companyName":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","companyId":"shanghai-fosun-pharmaceutical-industrial-development-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FCN-159 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}